The title compounds, C14H12O, (I), and C15H11BrO2, (II), were prepared and characterized as part of our studies of potential new photo-acid generators. In (I), which crystallizes in the ortho-rhom-bic space group Pca21, compared to P21/n for the previously known monoclinic polymorph [Cornella & Martin (2013 ▸). Org. Lett. 15, 6298-6301], the dihedral angle between the aromatic rings is 4.35 (6)° and the OH group is disordered over two sites in a 0.795 (3):0.205 (3) ratio. In the crystal of (I), mol-ecules are linked by O-H⋯π inter-actions involving both the major and minor -OH disorder components, generating [001] chains as part of the herringbone packing motif. The asymmetric unit of (II) contains two mol-ecules with similar conformations (weighted r.m.s. overlay fit = 0.183 Å). In the crystal of (II), both mol-ecules form carboxyl-ate inversion dimers linked by pairs of O-H⋯O hydrogen bonds, generating R 2 (2)(8) loops in each case. The dimers are linked by pairs of C-H⋯O hydrogen bonds to form [010] chains.
Rhodanine has been recognized as a privileged scaffold in medicinal chemistry due to its well-known ability to demonstrate a broad range of biological activities. The possibility of structural diversification has contributed to the significance of rhodanine structure in effective drug discovery and design. Many studies have confirmed the potential of rhodanine-derived compounds in the treatment of different types of cancer through the apoptosis induction mechanism. Furthermore, most of the rhodanine derivatives exhibited remarkable anticancer activity in the micromolar range while causing negligible cytotoxicity to normal cells. This review critically describes the anticancer activity profile of reported rhodanine compounds and the structure-activity relationships (SAR) to highlight the value of rhodanine as the core structure for future cancer drug development as well as to assist the researchers in rational drug design.